Our Communities
Advancing Earlier Alzheimer’s Answers for All
Discover how pTau217 testing using the ALZpath antibody supports patients, clinicians, and researchers.
Alzheimer’s disease touches many lives, from patients seeking early detection and clarity about their own health to clinicians providing care as they help patients make informed decisions, to researchers driving discovery to change what’s possible.
Developed for accuracy, built for access and backed by world-class science, ALZpath’s proprietary pTau217 antibody is helping redefine how – and when – Alzheimer’s disease pathology is detected.
Explore the sections below to understand how we’re working to advance earlier answers for all.
For Clinicians
Find out how ALZpath’s proprietary pTau217 antibody powers blood tests that will make earlier detection and more informed care possible for your patients.
For Researchers
Discover how ALZpath collaborates with researchers, clinical trial groups, and diagnostic developers to advance biomarker science and accelerate translation to clinical use.
For Patients
Learn how blood-based pTau217 testing is being used by the community to understand Alzheimer’s disease pathology and inform decision making with the ultimate goal of preserving quality of life.
Sensitive. Accurate. Early.
Research has shown that pTau217 reveals Alzheimer’s-related changes in the blood long before symptoms appear – pointing to a future with earlier answers for patients and earlier treatments.
Connect With Us
Reach out to our team to learn more about ALZpath, pTau217 testing, and how we’re partnering with communities to advance earlier Alzheimer’s disease detection.
